Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Thompson

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Thyroid : Official Journal of the American Thyroid Association|October 3, 2013
A preoperative nomogram for the prediction of ipsilateral central compartment lymph node metastases in papillary thyroid cancerAndrew M Thompson, Robin M Turner, Andrew Hayen, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2008
Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinasesJeff B Smaill, Ho H Lee, Brian D Palmer, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced SolubilityAndrew M Thompson, Patrick D O'Connor, Vanessa Yardley, et al.
Bioorganic & Medicinal Chemistry Letters|December 2, 2017
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxidesAndrew M Thompson, Andrew J Marshall, Louis Maes, et al.
Journal of Medicinal Chemistry|February 23, 2016
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Adrian Blaser, et al.
Bioorganic & Medicinal Chemistry Letters|May 3, 2017
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseasesAndrew M Thompson, Adrian Blaser, Brian D Palmer, et al.
European Journal of Medicinal Chemistry|December 3, 2020
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisalAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
European Journal of Medicinal Chemistry|February 13, 2026
New antitubercular pretomanid analogues as potent payloads in polymeric micelles: Leveraging zebrafish assays to accelerate lead optimisationAndrew M Thompson, Nils-Jørgen K Dal, Francesca Boldrin, et al.
Journal of Medicinal Chemistry|August 4, 2006
4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitutionBrian D Palmer, Andrew M Thompson, R John Booth, et al.
Journal of Medicinal Chemistry|February 21, 2018
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Thyroid : Official Journal of the American Thyroid Association|October 3, 2013
A preoperative nomogram for the prediction of ipsilateral central compartment lymph node metastases in papillary thyroid cancerAndrew M Thompson, Robin M Turner, Andrew Hayen, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2008
Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinasesJeff B Smaill, Ho H Lee, Brian D Palmer, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced SolubilityAndrew M Thompson, Patrick D O'Connor, Vanessa Yardley, et al.
Bioorganic & Medicinal Chemistry Letters|December 2, 2017
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxidesAndrew M Thompson, Andrew J Marshall, Louis Maes, et al.
Journal of Medicinal Chemistry|February 23, 2016
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Adrian Blaser, et al.
Bioorganic & Medicinal Chemistry Letters|May 3, 2017
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseasesAndrew M Thompson, Adrian Blaser, Brian D Palmer, et al.
European Journal of Medicinal Chemistry|December 3, 2020
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisalAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
European Journal of Medicinal Chemistry|February 13, 2026
New antitubercular pretomanid analogues as potent payloads in polymeric micelles: Leveraging zebrafish assays to accelerate lead optimisationAndrew M Thompson, Nils-Jørgen K Dal, Francesca Boldrin, et al.
Journal of Medicinal Chemistry|August 4, 2006
4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitutionBrian D Palmer, Andrew M Thompson, R John Booth, et al.
Journal of Medicinal Chemistry|February 21, 2018
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Pageof 4